{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["13(1)"],"submitter":["Caron NS"],"funding":["Bev Hartig Huntington&apos;s Disease Foundation","Huntington&apos;s Disease Society of America"],"pubmed_abstract":["<h4>Background</h4>Therapeutic approaches aimed at lowering toxic mutant huntingtin (mHTT) levels in the brain can reverse disease phenotypes in animal models of Huntington's disease (HD) and are currently being evaluated in clinical trials. Sensitive and dynamic response biomarkers are needed to assess the efficacy of such candidate therapies. Neurofilament light chain (NfL) is a biomarker of neurodegeneration that increases in cerebrospinal fluid (CSF) and blood with progression of HD. However, it remains unknown whether NfL in biofluids could serve as a response biomarker for assessing the efficacy of disease-modifying therapies for HD.<h4>Methods</h4>Longitudinal plasma and cross-sectional CSF samples were collected from the YAC128 transgenic mouse model of HD and wild-type (WT) litter"],"journal":["Translational neurodegeneration"],"pagination":["50"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11460072"],"repository":["biostudies-literature"],"pubmed_title":["Elevated plasma and CSF neurofilament light chain concentrations are stabilized in response to mutant huntingtin lowering in the brains of Huntington's disease mice."],"pmcid":["PMC11460072"],"pubmed_authors":["Hawellek DJ","Bone JN","Aly AE","Byrne LM","Lemarie FL","McColgan P","Caron NS","Casal LL","Wild EJ","Hayden MR","Ko S","Leavitt BR","Anderson C","Hill AM"],"additional_accession":[]},"is_claimable":false,"name":"Elevated plasma and CSF neurofilament light chain concentrations are stabilized in response to mutant huntingtin lowering in the brains of Huntington's disease mice.","description":"<h4>Background</h4>Therapeutic approaches aimed at lowering toxic mutant huntingtin (mHTT) levels in the brain can reverse disease phenotypes in animal models of Huntington's disease (HD) and are currently being evaluated in clinical trials. Sensitive and dynamic response biomarkers are needed to assess the efficacy of such candidate therapies. Neurofilament light chain (NfL) is a biomarker of neurodegeneration that increases in cerebrospinal fluid (CSF) and blood with progression of HD. However, it remains unknown whether NfL in biofluids could serve as a response biomarker for assessing the efficacy of disease-modifying therapies for HD.<h4>Methods</h4>Longitudinal plasma and cross-sectional CSF samples were collected from the YAC128 transgenic mouse model of HD and wild-type (WT) litter","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Oct","modification":"2026-07-14T19:43:45.891Z","creation":"2025-04-04T02:29:50.17Z"},"accession":"S-EPMC11460072","cross_references":{"pubmed":["39380076"],"doi":["10.1186/s40035-024-00443-8"]}}